• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Integer Appoints Michael Coyle to Board of Directors

    7/10/25 4:52:01 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ITGR alert in real time by email

    ~ New Director Brings Extensive Medical Device Industry Leadership and Technology Experience to Integer Board ~

    PLANO, Texas, July 10, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced it has appointed Michael Coyle to its Board of Directors.

    Coyle brings more than 40 years of leadership in the medical device industry to Integer and joins the Board as a member of the Audit Committee, Compensation & Organization Committee, and Technology Strategy Committee.

    He most recently served as president and CEO of iRhythm Technologies, a digital healthcare company. Before that, he was executive vice president and group president of Medtronic's cardio and vascular group and held leadership roles at St. Jude Medical and Eli Lilly earlier in his career.

    Coyle is currently a director on the Haemonetics Corporation and BaroPace boards and previously held positions on the boards of VNUS Medical Technologies, Inc. and Volcano Corporation.

    He earned a master's degree in business administration from the Wharton School of Business, University of Pennsylvania, and a bachelor's degree from Case Western Reserve University. He additionally holds six U.S. patents related to cardiovascular medical device products and technologies.

    "Integer's Board regularly evaluates its composition to ensure it encompasses the appropriate skills, background and perspectives necessary to drive growth for Integer's shareholders," said Pamela Bailey, Integer Board Chair. "We are pleased to welcome Michael Coyle, whose extensive medical device industry experience and proven leadership in global business and technology will contribute significantly to our strategic initiatives and culture."

    "The executive leadership team and I look forward to working with Michael as we execute our strategy to deliver sustained outperformance," said Joseph Dziedzic, Integer president and CEO. "We are confident Michael's expertise will contribute to Integer's contract development and manufacturing outsourcing strategy, furthering our position as our customers' partner of choice for innovative medical technologies and services as we realize our vision to enhance the lives of patients worldwide."



    About Integer®

    Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, the Company is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The Company's brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at www.integer.net.

    Investor Relations:Media Relations:
    Kristen StewartKelly Butler
    [email protected][email protected]
    551.337.3973469.731.6617


    Primary Logo

    Get the next $ITGR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ITGR

    DatePrice TargetRatingAnalyst
    5/22/2025$140.00Neutral → Buy
    Citigroup
    3/28/2025$145.00Outperform
    Raymond James
    2/21/2025Outperform → Perform
    Oppenheimer
    12/3/2024$160.00Overweight
    Wells Fargo
    7/16/2024$135.00Outperform
    Oppenheimer
    5/15/2024$137.00Buy
    Truist
    4/15/2024$105.00 → $135.00Neutral → Buy
    BofA Securities
    3/14/2024$137.00Buy
    CL King
    More analyst ratings

    $ITGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Coyle Michael J was granted 1,355 shares (SEC Form 4)

      4 - Integer Holdings Corp (0001114483) (Issuer)

      7/14/25 7:08:10 PM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 3 filed by new insider Coyle Michael J

      3 - Integer Holdings Corp (0001114483) (Issuer)

      7/14/25 7:05:47 PM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • President & CEO Dziedzic Joseph W converted options into 36,202 shares and covered exercise/tax liability with 13,395 shares, increasing direct ownership by 99% to 45,807 units (SEC Form 4)

      4 - Integer Holdings Corp (0001114483) (Issuer)

      6/13/25 6:09:03 PM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ITGR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Integer Appoints Michael Coyle to Board of Directors

      ~ New Director Brings Extensive Medical Device Industry Leadership and Technology Experience to Integer Board ~ PLANO, Texas, July 10, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced it has appointed Michael Coyle to its Board of Directors. Coyle brings more than 40 years of leadership in the medical device industry to Integer and joins the Board as a member of the Audit Committee, Compensation & Organization Committee, and Technology Strategy Committee. He most recently served as president and CEO of iRhythm Technologies, a digital healthcare company. Bef

      7/10/25 4:52:01 PM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Integer Holdings Corporation Announces Conversion Period for 2.125% Convertible Senior Notes due 2028

      PLANO, Texas, July 02, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) ("Integer" or the "Company"), a leading medical device contract development and manufacturing organization, today notified holders of its 2.125% Convertible Senior Notes due 2028 (the "Notes") that the Notes are convertible, at the option of the holders (the "Conversion Option") beginning on July 1, 2025, and ending at the close of business on September 30, 2025. The Notes are convertible into cash, up to the principal amount of the Notes, and in cash, shares of the Company's common stock or a combination thereof, at the Company's election, in respect of the remainder, if any, of the Company's conversi

      7/2/25 4:05:00 PM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Integer Announces Conference Call to Discuss Second Quarter 2025 Results

      PLANO, Texas, June 26, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) announced today that it will webcast its conference call discussing financial results and business highlights for the second quarter ended June 27, 2025, on Thursday, July 24, 2025, at 8 a.m. CT / 9 a.m. ET. Other forward-looking and material information may also be discussed during this call. The company will issue a news release announcing financial results for the second quarter on July 24 prior to the conference call. Conference call details: Date: Thursday, July 24, 2025Time: 8 a.m. CT / 9 a.m. ETDomestic dial-in number: (800) 715-9871International dial-in number: (646) 307-1963Conference ID: 31

      6/26/25 8:00:00 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ITGR
    SEC Filings

    See more
    • Integer Holdings Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Integer Holdings Corp (0001114483) (Filer)

      7/10/25 4:58:33 PM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Integer Holdings Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Integer Holdings Corp (0001114483) (Filer)

      7/2/25 4:10:31 PM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Integer Holdings Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Integer Holdings Corp (0001114483) (Filer)

      5/28/25 7:08:15 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ITGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Integer Holdings upgraded by Citigroup with a new price target

      Citigroup upgraded Integer Holdings from Neutral to Buy and set a new price target of $140.00

      5/22/25 8:16:14 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Raymond James initiated coverage on Integer Holdings with a new price target

      Raymond James initiated coverage of Integer Holdings with a rating of Outperform and set a new price target of $145.00

      3/28/25 8:19:38 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Integer Holdings downgraded by Oppenheimer

      Oppenheimer downgraded Integer Holdings from Outperform to Perform

      2/21/25 6:56:47 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ITGR
    Leadership Updates

    Live Leadership Updates

    See more
    • Integer Appoints Michael Coyle to Board of Directors

      ~ New Director Brings Extensive Medical Device Industry Leadership and Technology Experience to Integer Board ~ PLANO, Texas, July 10, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced it has appointed Michael Coyle to its Board of Directors. Coyle brings more than 40 years of leadership in the medical device industry to Integer and joins the Board as a member of the Audit Committee, Compensation & Organization Committee, and Technology Strategy Committee. He most recently served as president and CEO of iRhythm Technologies, a digital healthcare company. Bef

      7/10/25 4:52:01 PM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Eargo Announces Strategic Additions to Board of Directors Following Patient Square Capital Becoming New Majority Shareholder

      SAN JOSE, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. ("Eargo" or the "Company") (NASDAQ:EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the appointments of several new directors following the closing of the Company's rights offering as previously announced on November 29, 2022. Patient Square Capital became the Company's majority owner upon closing of the rights offering and conversion of Patient Square's senior secured convertible notes per its investment in June 2022. As previously announced, following the completion of the rights offering, Patient Square has the right to nominate a number of directors t

      12/7/22 4:05:00 PM ET
      $EAR
      $ITGR
      $VAPO
      Medical Specialities
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Medical/Dental Instruments
    • Integer Announces Board Leadership Transition

      PLANO, Texas, March 17, 2022 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device outsource (MDO) manufacturer, announced today that Bill R. Sanford will be retiring as Chair of the Integer Board of Directors at the conclusion of the Company's 2022 annual meeting of stockholders, which is scheduled to be held on May 18, 2022. Commensurate with this carefully planned transition, the Board of Directors plans to appoint current long-standing Integer Board member Pamela G. Bailey to serve as the next Chair of the Board. "On behalf of the Integer Board of Directors, I wish to thank Bill for his immense contribution and insightful leadership over the past 22 ye

      3/17/22 8:00:00 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ITGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Integer Holdings Corporation (Amendment)

      SC 13G/A - Integer Holdings Corp (0001114483) (Subject)

      2/9/24 9:59:01 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Integer Holdings Corporation (Amendment)

      SC 13G/A - Integer Holdings Corp (0001114483) (Subject)

      1/30/24 1:15:44 PM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Integer Holdings Corporation (Amendment)

      SC 13G/A - Integer Holdings Corp (0001114483) (Subject)

      2/10/23 2:42:23 PM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ITGR
    Financials

    Live finance-specific insights

    See more
    • Integer Announces Conference Call to Discuss Second Quarter 2025 Results

      PLANO, Texas, June 26, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) announced today that it will webcast its conference call discussing financial results and business highlights for the second quarter ended June 27, 2025, on Thursday, July 24, 2025, at 8 a.m. CT / 9 a.m. ET. Other forward-looking and material information may also be discussed during this call. The company will issue a news release announcing financial results for the second quarter on July 24 prior to the conference call. Conference call details: Date: Thursday, July 24, 2025Time: 8 a.m. CT / 9 a.m. ETDomestic dial-in number: (800) 715-9871International dial-in number: (646) 307-1963Conference ID: 31

      6/26/25 8:00:00 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Integer Announces CEO Succession Plan

      ~ Joseph Dziedzic to retire as President and CEO ~~ Payman Khales appointed President and CEO effective October 24, 2025 ~ PLANO, Texas, April 24, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device contract development and manufacturing organization, today announced that Joseph Dziedzic will retire as President and Chief Executive Officer and will step down from the Board of Directors, effective October 24, 2025. At that time, Payman Khales, Chief Operating Officer, will assume the President and CEO position and join the Company's Board. To ensure a smooth transition, Mr. Dziedzic will serve as an advisor to the Company through March 31, 2026. "We

      4/24/25 8:01:00 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Integer Holdings Corporation Reports First Quarter 2025 Results

      ~ Strong start to the year with 1Q25 financial results ~~ Reiterating 2025 sales and adjusted operating income outlook; raising adjusted EPS outlook ~ PLANO, Texas, April 24, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended March 28, 2025.   First Quarter 2025 Highlights (compared to First Quarter 2024, except as noted) Sales increased 7% to $437 million, with organic growth of 6%.GAAP operating income increased $11 million to $50 million, an increase of 28%. Non-GAAP adjusted operating income increased $9 million to $71 million, an increase of 14%.GAAP income (loss) from continuing operations decreased $43 million to a

      4/24/25 8:00:00 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care